William Blair Investment Management LLC Grows Stake in Hologic, Inc. (HOLX)

William Blair Investment Management LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 6.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,747 shares of the medical equipment provider’s stock after acquiring an additional 1,444 shares during the quarter. William Blair Investment Management LLC’s holdings in Hologic were worth $932,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in HOLX. Piedmont Investment Advisors LLC acquired a new stake in shares of Hologic in the second quarter worth $127,000. Bessemer Group Inc. increased its stake in shares of Hologic by 122.4% in the third quarter. Bessemer Group Inc. now owns 3,534 shares of the medical equipment provider’s stock worth $145,000 after acquiring an additional 1,945 shares during the period. Amussen Hunsaker Associates LLC acquired a new stake in shares of Hologic in the second quarter worth $159,000. Stratos Wealth Partners LTD. acquired a new stake in shares of Hologic in the third quarter worth $185,000. Finally, Lincoln Capital Corp acquired a new stake in shares of Hologic in the third quarter worth $201,000. Hedge funds and other institutional investors own 91.73% of the company’s stock.

Shares of NASDAQ HOLX opened at $41.98 on Friday. Hologic, Inc. has a 1 year low of $35.10 and a 1 year high of $45.17. The firm has a market cap of $12.51 billion, a P/E ratio of 19.31, a PEG ratio of 2.00 and a beta of 0.69. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 1.12.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). The company had revenue of $813.50 million for the quarter, compared to analysts’ expectations of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. On average, research analysts anticipate that Hologic, Inc. will post 2.4 EPS for the current year.

A number of analysts have recently weighed in on HOLX shares. Bank of America lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $47.00 to $42.00 in a research note on Thursday, September 13th. Royal Bank of Canada increased their price objective on shares of Hologic from $40.00 to $46.00 and gave the stock a “sector perform” rating in a research note on Friday, November 30th. They noted that the move was a valuation call. BidaskClub downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Thursday, August 16th. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Finally, Piper Jaffray Companies lowered their price target on shares of Hologic to $45.00 and set an “overweight” rating on the stock in a report on Thursday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $44.53.

In other Hologic news, Director Sally Crawford sold 13,257 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total transaction of $524,181.78. Following the transaction, the director now directly owns 167,701 shares of the company’s stock, valued at $6,630,897.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Allison P. Bebo sold 6,500 shares of the stock in a transaction on Friday, November 16th. The shares were sold at an average price of $42.00, for a total transaction of $273,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,276 shares of company stock worth $3,311,802. Insiders own 0.79% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.wkrb13.com/2018/12/08/william-blair-investment-management-llc-grows-stake-in-hologic-inc-holx.html.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Consumer Price Index (CPI)

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply